Table 1.

Intervention ingredients per-treatment arm

Treatment arms
A*	B (PLP10)*	C*	Placebo*
Intervention: EPA (1650 mg)/DHA (4650 mg)/GLA (2000 mg)/LA (3850 mg)/total other Ω-3 (600 mg)†/total MUFA‡ (1714 mg)+total SFA (18:0 160 mg, 16:0 650 mg)/vitamin A (0.6 mg)/vitamin E (22 mg) plus citrus aroma	Intervention: EPA (1650 mg)/DHA (4650 mg)/GLA (2000 mg)/LA (3850 mg)/total other Ω-3 (600 mg) †/total MUFA‡ (1714 mg)+total SFA (18:0 160 mg, 16:0 650 mg)/vitamin A (0.6 mg)/vitamin E (22 mg)+pure γ-tocopherol (760 mg) plus citrus aroma	Intervention: Pure natural γ-tocopherol (760 mg) dispersed in pure virgin olive oil (16137 mg) as delivery vehicle plus citrus aroma	Intervention: Olive oil (pure virgin) plus citrus aroma

*Total daily dose: 19.5 ml.

†Other Ω-3: C18:3n−3 37 mg, C18:4n−3 73 mg, C20:4n−3 98 mg, C22:5n−3 392 mg.

‡MUFA: 18:1 1300 mg, 20:1 250 mg, 22:1 82 mg, 24:1 82 mg.

EPAX 1050, EPAX AS, Aalesund, Norway, was used as the source for the Ω-3 PUFAs, as re-esterified glycerides from fish body oils; borage seed oil (organic, cold pressed) ‘Borago officinalis’ Goerlich Pharma International GmbH, Edling, Germany, was used as the source for the Ω-6 PUFAs, MUFAs and SFAs, as triglycerides. The pure natural γ-tocopherol was purchased from Tama Biochemical Co Ltd, Shinjuku-ku Tokyo, Japan; vitamin A, as β-carotene, from HealthAid Ltd, Middlesex, UK and the citrus aroma from Givaudan Schwaiz AG, Dubendorf, Switzerland.

DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GLA, γ-linolenic acid; LA, linoleic acid.